혈관운동 증상 시장 규모, 점유율, 성장 분석 : 치료법별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Vasomotor Symptoms Market size was valued at USD 4 Billion in 2024 and is poised to grow from USD 4.27 Billion in 2025 to USD 7.29 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

Vasomotor symptoms, prominently recognized among menstruation-related health concerns, primarily include hot flashes, night sweats, and episodes of anemia. These symptoms often present as sudden flushing of the face, neck, and forehead accompanied by excessive sweating. The intensity and frequency of heart palpitations significantly differ among postmenopausal women, with a particularly challenging experience observed during the early stages of menopause. The impact of these symptoms can be quite severe, affecting daily life and well-being. For many women, these symptoms can persist, emphasizing the individualized nature of the menopausal experience. Additionally, multifaceted neurological manifestations underscore the importance of acknowledging the unique challenges confronted by women in this transformative phase, necessitating focused solutions and support.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segments Analysis

Global Vasomotor Symptoms Market is segmented by Therapy Type, Distribution Channel, End User and region. Based on Therapy Type, the market is segmented into Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Stores. Based on End User, the market is segmented into Hospitals and Clinics, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vasomotor Symptoms Market

Research and development initiatives, along with clinical trials, are crucial for enhancing our comprehension of the mechanisms behind neurological symptoms, including associated mutations and physiological variations. This deeper knowledge can lead to the creation of more targeted and effective therapies, as researchers delve into the intricate nature of neurological disorders. By conducting clinical trials, the market benefits from an expanded array of treatment options, which, in turn, spurs growth by introducing groundbreaking solutions. The commitment to exploring and understanding these complexities significantly contributes to the overall expansion and advancement of the Vasomotor Symptoms market.

Restraints in the Vasomotor Symptoms Market

The expansion of the Vasomotor Symptoms market is impeded by the significant costs related to various treatment options. A considerable number of companies dedicate substantial resources to the research and development of innovative therapies aimed at improving recovery outcomes. However, this commitment results in increased overall expenses that can burden both healthcare providers and patients. While advancements in treatment hold the potential to enhance patient care and efficacy, the associated high costs present a substantial barrier to market growth. Consequently, the financial implications of these innovations may deter broader accessibility and adoption within the healthcare landscape.

Market Trends of the Vasomotor Symptoms Market

The vasomotor symptoms (VMS) market is witnessing a significant upward trend driven by heightened awareness of these symptoms and the importance of effective treatments. As new interventions and treatments emerge, more women are actively seeking symptom relief, resulting in an expanding market. Companies specializing in innovative products or novel treatment approaches position themselves advantageously, capturing the interest of both healthcare professionals and patients. Establishing a treatment as the preferred option can solidify a company's reputation and market share, making strategic innovation and marketing essential for success in this evolving landscape, as the demand for effective VMS management continues to grow.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vasomotor Symptoms Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Estrogen
• Progesterone
• Combination
• OTC hormone
• Anti-Depressants
• Others

Global Vasomotor Symptoms Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Global Vasomotor Symptoms Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Specialty Centers
• Others

Global Vasomotor Symptoms Market Size & CAGR (2026-2033)

• North America (Therapy Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• TherapeuticsMD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KaNDy Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fervent Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sojournix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations